THE VALUE OF IODIDE SYMPORTER FOR PROGNOSIS OF BREAST CANCER OF DIFFERENT MOLECULAR SUBTYPES
Keywords:
breast cancer, Na+/I– symporter (NIS), prognosis, molecular subtype.Abstract
Summary. Objective: to investigate the features of expression of the Na+/I– symporter (NIS) in tumor cells of
patients and evaluate its clinical significance for prognosis of breast cancer (BC) of a certain molecular subtype.
Materials and methods: 126 patients with BC of stage
I–II aged 27 to 75 years (mean age — 53,2±4.1 years)
who were hospitalized in the Precarpathian Clinical Oncology Center during 2005–2015 years; clinical, immunohistochemical, morphological and statistical methods
were used. Results: it was demonstrated that the expression of NIS in tumor tissue is directly correlated with
the stage of disease, development of metastases in regional lymph nodes and depends on the proliferative activity and expression of intercellular adhesion molecules
in tumor tissue of patients with luminally A, luminally B and basal subtype of BC. Found that overall survival of patients with BC luminali B and basal molecular subtype is significantly worse in the presence of the
tumors the expression of NIS in the absence of E-cadherin, the presence of N-cadherin and CD44 and high
proliferative activity of tumor cells. Conclusion: the results suggest that the expression of NIS in the tissue of tumors is associated with unfavorable course of BC luminal B and basal molecular subtypes Indicators of NIS
expression in tumor cells can be used as additional criteria for prediction of clinical course of BC luminal B
and basal molecular subtypes of BC.
References
Рак в Україні, 2014–2015. Захворюваність, смертність, показники діяльності онкологічної служби. Бюл Нац канцерреєстру України 2016; (17): 46–7.
Смоланка ІІ, Скляр СЮ. Шляхи підвищення ефективності комплексного лікування хворих на рак молочної залози. Київ: Сталь, 2007. 192 с.
Hennigs A, Riedel F, Gondos A. Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. BMC Cancer 2016; 16 (1): 734.
Сивак ЛА, Верьовкіна НО, Лялькін СА. Прогностичні фактори при раку грудної залози. Сучасний стан проблеми. Клін онкол 2014; (4 (16)): 46–9.
Langlands FE, Horgan K, Dodwell DD, et al. Breast cancer subtypes: response to radiotherapy and potential radiosensitisation. Br J Radiol 2013; 86: 623–37.
Nassar A, Radhakrishnan A, Cabrero I, et al. Intratumoral heterogeneity of immunohistochemical marker expression in breast carcinoma: A tissue microarray-based study. Appl Immunohistochem Mol Morphol 2010; 18 (5): 433–41.
Чехун ВФ, Шербан СД, Савцова ЗД. Гетерогенность опухоли — динамическое состояние. Онкология 2012; 14 (1): 4–12.
Boyle DP, McCourt CM, Matchett KB, et al. Molecular and clinicopathological markers of prognosis in breast cancer. Expert Rev Mol Diagnostics 2013; 13: 481–98.
Kogai T, Taki K, Brent GA. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer Clin 2006; 13 (3): 797–826.
Micali S, Bulotta S, Puppin C, et al. Sodium iodide symporter in extrathyroidal malignancies: focus on breast and urological cancer. Cancer 2014; 14: 303–9.
Renier C, Yao C, Goris M, et al. Endogenous NIS expression in triple-negative breast cancers. Ann Surg Oncol 2009; 16: 962–8.
Semba R, Delange F. Iodine in human milk: perspectives for infant health. Nutr Rev 2001; 59 (8 Pt 1): 269–78.
Smyth P, Shering S, Kilban M, et al. Serum thyroid peroxidase autoantibodies, thyroid volume, and outcome in breast carcinoma. J Clin Endocrin Metab 1998; 83 (8): 2711–6.
Hansen RK, Bissell MJ. Tissue archistructure and breast cancer: the role of extracellular matrix and steroid hormones MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Endocr Relat Cancer 2000; 17 (2): 95–113.
Lukianova NY, Andriiv AV, Chekhun VF. Correlation of iodine symporter expression in highly and low malignant cell lines of human breast cancer differed in their sensitivity to doxorubicin. Exp Oncology 2016; 38 (3): 169–71.
McClelland RA, Wilson D, Leake R. A multicentre study into the reliability of steroid receptor immunocyto-chemical assay quantification. Eur J Cancer 1991; 27: 711–5.
Hansen RK, Bissell MJ. Tissue archistructure and breast cancer: the role of extracellular matrix and steroid hormones. Endoc Relat Cancer 2000; 7 (2): 95–113.
Ryan J, Curran C, Hennessy E, et al. The sodium iodidesymporter (NIS) and potential regulators in normal, benign and malignant human breast tissue. PLoS One 2011; 6 (1): 160–3.
Kumar R, Tiwari RK. Application of microarray in breast cancer: аn overview. J Pharm Bioallied Sci 2012; 4 (1): 21–6.
Tandon A, Shrivastava A, Kumar A, et al. Sodium iodide symporter, estrogen receptor, and progesterone receptor expression in carcinoma breast — an immunohistochemical analysis. Indian J Pathol Microbiol 2011; 54 (4): 745–51.
Bourgeois P, Bedard PL, Sirtaine N, et al. Differential expression of the Na+/I− symporter by endocrine receptor status: a potential new therapeutic target in estrogen receptor negative high grade breast cancers. Translat Biomed 2015; Special Issue: 1–9.
